XLXiaomin Luo

Xiaomin Luo

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Xiaomin Luo has a total of 66 co-authors. Here are the top co-authors by number of shared publications:

  • Changlin Liu

    Shenzhen Key Laboratory of Viral Oncology, Shenzhen Hospital of Southern Medical University, Guangdong, China

    2 shared publications
  • Chuping Ni

    Shenzhen Key Laboratory of Viral Oncology, Shenzhen Hospital of Southern Medical University, Guangdong, China

    2 shared publications
  • Min Zhao

    PANACRO (Hefei) Pharmaceutical Technology Co. Ltd., Hefei, China

    2 shared publications
  • Xin Li

    Shenzhen Key Laboratory of Viral Oncology, Shenzhen Hospital of Southern Medical University, Guangdong, China

    2 shared publications
  • Yuanbin Zhang

    Shenzhen Key Laboratory of Viral Oncology, Shenzhen Hospital of Southern Medical University, Guangdong, China

    2 shared publications
  • Caiyun Zhang

    School of Biomedical Sciences, The Chinese University of Hong Kong, Sha Tin, China

    1 shared publication

Latest Publications

  • Open Access

    Exogenous Epstein–Barr virus nuclear antigen 1 induces ADAR1-driven tumor resistance against immunotherapy

    by Changlin Liu, Zhiqiang Sun, Chao Li, Yanqing Zhou, Xuefeng Gao, Yuping Zhong, Xiaomin Luo, Chenci Wang, Yuanbin Zhang, Chuping Ni, et al.

    Immune checkpoint blockade (ICB) therapy continues to face limitations due to tumor resistance linked to suppressed interferon (IFN) signaling. This suppression can be attributed to multiple mechanisms, among which viral pathogens represent a compelling though not yet fully elucidated factor. Here, we demonstrate that exogenous Epstein–Barr virus-encoded EBNA1 drives immunosuppression via enhanced RNA-editing enzyme ADAR1-mediated RNA editing. Comparative tumor model analyses revealed that EBNA1 overexpression reduced CD8 + T-cell infiltration, inhibited IFN responses, polarized macrophages toward the M2 phenotype, and accelerated tumor growth. Mechanistically, EBNA1 forms a trimeric complex with insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) and eukaryotic translation initiation factor 4G1 (EIF4G1), enhancing ADAR1 translation. Elevated ADAR1 further increased A-to-I editing of dsRNA, particularly within SINE elements near IFN-associated genes. This editing masked immunostimulatory signals, impairing RNA sensor activation and blunting IFN pathways. Notably, combining the EBNA1-targeting PROTAC degrader EP-1215 with anti-PD-1 effectively restored IFN signaling, enhanced T-cell infiltration, and suppressed EBNA1 + tumors in humanized mice. This viral exploitation of RNA editing suggests that targeting EBNA1 could be a strategy to convert “cold” tumors into “hot” targets amenable to ICB therapy.


  • Open Access

    Interferon-induced transmembrane protein-1 competitively blocks Ephrin receptor A2-mediated Epstein–Barr virus entry into epithelial cells

    by Yinggui Yang, Tengteng Ding, Ying Cong, Xiaomin Luo, Changlin Liu, Ting Gong, Min Zhao, Xichun Zheng, Chenglin Li, Yuanbin Zhang, et al.

    Epstein–Barr virus (EBV) can infect both B cells and epithelial cells (ECs), causing diseases such as mononucleosis and cancer. It enters ECs via Ephrin receptor A2 (EphA2). The function of interferon-induced transmembrane protein-1 (IFITM1) in EBV infection of ECs remains elusive. Here we report that IFITM1 inhibits EphA2-mediated EBV entry into ECs. RNA-sequencing and clinical sample analysis show reduced IFITM1 in EBV-positive ECs and a negative correlation between IFITM1 level and EBV copy number. IFITM1 depletion increases EBV infection and vice versa. Exogenous soluble IFITM1 effectively prevents EBV infection in vitro and in vivo. Furthermore, three-dimensional structure prediction and site-directed mutagenesis demonstrate that IFITM1 interacts with EphA2 via its two specific residues, competitively blocking EphA2 binding to EBV glycoproteins. Finally, YTHDF3, an m6A reader, suppresses IFITM1 via degradation-related DEAD-box protein 5 (DDX5). Thus, this study underscores IFITM1’s crucial role in blocking EphA2-mediated EBV entry into ECs, indicating its potential in preventing EBV infection.


  • Open Access

    Distinct Roles of TRAPPC8 and TRAPPC12 in Ciliogenesis via Their Interactions With OFD1

    by Caiyun Zhang, Chunman Li, Gavin Ka Yu Siu, Xiaomin Luo, Sidney Yu

    The transport protein particle (TRAPP) complex was initially identified as a tethering factor for COPII vesicle. Subsequently, three forms (TRAPPI, II, and III) have been found and TRAPPIII has been reported to serve as a regulator in autophagy. This study investigates a new role of mammalian TRAPPIII in ciliogenesis. We found a ciliopathy protein, oral-facial-digital syndrome 1 (OFD1), interacting with the TRAPPIII-specific subunits TRAPPC8 and TRAPPC12. TRAPPC8 is necessary for the association of OFD1 with pericentriolar material 1 (PCM1). Its depletion reduces the extent of colocalized signals between OFD1 and PCM1, but does not compromise the structural integrity of centriolar satellites. The interaction between TRAPPC8 and OFD1 inhibits that between OFD1 and TRAPPC12, suggesting different roles of TRAPPIII-specific subunits in ciliogenesis and explaining the differences in cilium lengths in TRAPPC8-depleted and TRAPPC12-depleted hTERT-RPE1 cells. On the other hand, TRAPPC12 depletion causes increased ciliary length because TRAPPC12 is required for the disassembly of primary cilia. Overall, this study has revealed different roles of TRAPPC8 and TRAPPC12 in the assembly of centriolar satellites and demonstrated a possible tethering role of TRAPPIII during ciliogenesis.


  • TBC1D20 Is Essential for Mouse Blood–Testis Barrier Integrity Through Maintaining the Epithelial Phenotype and Modulating the Maturation of Sertoli Cells

    by Lina Cui, Yanli Gu, Shuo Liu, Minghua Li, Jing Ye, Fanting Zhang, Xiaomin Luo, Wen-Lin Chang, Yaoting Gui

    Sertoli cells are important for spermatogenesis not only by directly interacting with germ line cells in the seminiferous epithelium but also by constituting the blood–testis barrier (BTB) structure to create a favorable environment for spermatogenesis. Blind sterile (bs) male mice are infertile, with excessive germ cell apoptosis and spermatogenesis arrest. TBC1D20 (TBC1 domain family member 20) deficiency has been identified as the causative mutation in bs mice. However, whether TBC1D20 loss of function also impairs BTB integrity, which further contributes to the failed spermatogenesis of bs male mice, remains unclear. In the present study, biotin tracer assay and transmission electron microscopy showed severely disrupted BTB integrity in bs testes. Compared to the wild-type Sertoli cells, BTB components of cultured bs Sertoli cells in vitro was perturbed with downregulation of E-cadherin, ZO-1, β-catenin, and Claudin 11. The obvious rearrangement of F-actin indicated disrupted epithelial–mesenchymal balance in TBC1D20-deficient Sertoli cells. The ability of bs Sertoli cells to maintain the clone formation of spermatogonia stem cells was also obviously limited. Furthermore, the decreasing of SOX9 (sex-determining region Y box 9) and WT1 (Wilms’ tumor 1) and increasing of vimentin in bs Sertoli cells indicated that TBC1D20 loss of function attenuated the differentiation progression of bs Sertoli cells. In summary, TBC1D20 loss of function impedes the maturation of adult Sertoli cells and resulted in impaired BTB integrity, which is further implicated in the infertile phenotype of bs male mice.


  • Critical Role of Antimicrobial Peptide Cathelicidin for Controlling Helicobacter pylori Survival and Infection

    by Lin Zhang, William K. K. Wu, Richard L. Gallo, Evandro F. Fang, Wei Hu, Thomas K. W. Ling, Jing Shen, Ruby L. Y. Chan, Lan Lu, Xiao M. Luo, et al.

    The antimicrobial peptide cathelicidin is critical for protection against different kinds of microbial infection. This study sought to elucidate the protective action of cathelicidin against Helicobacter pylori infection and its associated gastritis. Exogenous cathelicidin was found to inhibit H. pylori growth, destroy the bacteria biofilm, and induce morphological alterations in H. pylori membrane. Additionally, knockdown of endogenous cathelicidin in human gastric epithelial HFE-145 cells markedly increased the intracellular survival of H. pylori. Consistently, cathelicidin knockout mice exhibited stronger H. pylori colonization, higher expression of proinflammatory cytokines IL-6, IL-1β, and ICAM1, and lower expression of the anti-inflammatory cytokine IL-10 in the gastric mucosa upon H. pylori infection. In wild-type mice, H. pylori infection also stimulated gastric epithelium-derived cathelicidin production. Importantly, pretreatment with bioengineered Lactococcus lactis that actively secretes cathelicidin significantly increased mucosal cathelicidin levels and reduced H. pylori infection and the associated inflammation. Moreover, cathelicidin strengthened the barrier function of gastric mucosa by stimulating mucus synthesis. Collectively, these findings indicate that cathelicidin plays a significant role as a potential natural antibiotic for H. pylori clearance and a therapeutic agent for chronic gastritis.